Clinical trials: Bronchodilation
Asthma
A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)
The study will measure the improvement in lung function in subjects with asthma after inhaling from two inhalers, Albuterol in a dry powder inhaler and albuterol in an HFA (hydrofluoroalkane), metered dose inhaler.
- Trial name
- NCT01056159
- Testing
- Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Single Dose Bronchodilatory Study in Asthma
Study to evaluate the bronchodilator effects of Zyflo CR in patients with chronic stable asthma.
- Trial name
- NCT01805687
- Testing
- Zileuton extended release
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Cornerstone Therapeutics Inc.
Asthma
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics
The primary objective of this study is to evaluate the efficacy of Albuterol Spiromax® versus placebo in subjects with persistent asthma.
- Trial name
- NCT01747629
- Testing
- Albuterol MDPI
- Where
- 35 sites in United States
- Volunteers
- 160 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Pulmonary Disease, Chronic Obstructive
Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)
The primary objective of this Non Interventional Study is to measure changes in physical functioning, a surrogate for physical activity and exercise capacity, in COPD patients on treatment with Spiolto® Respimat® in routine daily…
- Trial name
- NCT02720757
- Testing
- Spiolto Respimat
- Where
- 6 sites in Belgium, Denmark and 4 more
- Volunteers
- 132 people
- Sponsor
- Boehringer Ingelheim
COPD
Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD
This is a phase 1/phase 2a, single dose, crossover study conducted in two parts. Part 1: Phase 1, open-label, 4-period crossover study in 8 healthy subjects to determine the optimal dose of AERO-001 and AERO-002, the active…
- Trial name
- NCT06841640
- Testing
- AERO-001, AERO-002, AERO-007
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AeroRx Therapeutics Inc.
Stable Asthma
Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler
The purpose of this study is to compare the therapeutic effects of formoterol in Symbicort with formoterol in Oxis Turbuhaler for the treatment of adults with stable asthma.
- Trial name
- NCT00658255
- Testing
- budesonide/formoterol, formoterol
- Volunteers
- 175 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease…
- Trial name
- INTRUST1 (NCT00846586)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 137 sites in United States, Argentina and 10 more
- Volunteers
- 1,134 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Effects of Salmeterol on Walking Capacity in Patients With COPD
This study was designed to test the following hypothesis: The acute changes in exercise tolerance during the endurance shuttle walk will be greater with salmeterol compared to placebo in patients with chronic obstructive…
- Trial name
- NCT00525564
- Testing
- Salmeterol diskus inhalation powder
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- Laval University
Chronic Obstructive Pulmonary Disease
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared…
- Trial name
- NCT02796677
- Testing
- Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg)
- Where
- 163 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,595 people
- Sponsor
- AstraZeneca
COPD, CT
Effects of Bronchodilation on Computed Tomography (CT) Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent.
CT studies considering bronchial dimensions in chronic obstructive pulmonary disease (COPD) were conducted without control of bronchodilation.
- Conditions
- COPD, CT, Bronchodilation
- Trial name
- NCT01142531
- Testing
- Chest CT scan
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Erasme University Hospital
Copd, Heart Failure
Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure
Double-blind, randomized, two-period crossover, placebo-controlled, single-center study, to determine the effect of umeclidinium/vilanterol 55/22 μg compared with placebo on the increase in left systolic chamber function during…
- Trial name
- CHHEF (NCT04522596)
- Testing
- Umeclidinium/vilanterol
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Luis Puente Maestu
Chronic Obstructive Pulmonary Disease Moderate, Chronic Obstructive Pulmonary Disease Severe
Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a lung condition characterized by chronic respiratory symptoms (dyspnoea, cough, sputum production and/or exacerbations) due to abnormalities of the airways (e.g.
- Conditions
- Chronic Obstructive Pulmonary Disease Moderate, Chronic Obstructive Pulmonary Disease Severe, Cardiovascular Diseases, Quality of Life
- Trial name
- NCT06072690
- Where
- Lithuania
- Volunteers
- 80 people
- Sponsor
- Lithuanian University of Health Sciences
Chronic Obstructive Pulmonary Disease (COPD)
Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study
Among many other causes, Bronchial obstruction in Chronic Obstructive Pulmonary Disease (COPD) is also caused by inflammation of peripheral airways walls.
- Trial name
- SANOB (NCT01853787)
- Testing
- Formoterol Fumarate, Salmeterol
- Where
- 2 sites in Italy
- Volunteers
- 49 people
- Sponsor
- University of Milan
COPD, Emphysema
Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema
To evaluate if tiotropium (Spiriva)induced bronchodilation of inspiratory capacity in patients with moderate to severe copd subjected to metronome paced hyperventilation induced dynamic hyperinflation is dependent upon the extent…
- Trial name
- NCT00570544
- Testing
- tiotropium
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Gelb, Arthur F., M.D.
Asthma
A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing
This is a one-year study to look at the safety of a dry powder inhaler with albuterol. After a one-week run in, for the first 3 months subjects will use an inhaler with either albuterol or a dummy drug at regular times four times…
- Trial name
- NCT01218009
- Testing
- Albuterol Spiromax
- Where
- 30 sites in United States
- Volunteers
- 331 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Obstructive Pulmonary Disease
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and…
- Trial name
- FAST (NCT01922271)
- Testing
- NVA237, Tiotropium, Salbutamol
- Where
- 14 sites in Germany
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Sensitivity of New Exercise Tests in Chronic Obstructive Pulmonary Disease (COPD)
This study was designed to test the following hypothesis: The 3-min constant rate step test and the 3-min constant rate shuttle walk test will be sensitive to detect improvement in exertional dyspnea following acute…
- Trial name
- NCT00807534
- Testing
- ipratropium bromide, constant rate step test, constant rate shuttle walk test
- Where
- 2 sites in Canada
- Volunteers
- 44 people
- Sponsor
- Laval University
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease (COPD), Lung Disease Chronic, Lung Diseases, Obstructive
- Trial name
- AERODUO-2 (NCT07896252)
- Testing
- AERO-001, AERO-002, AERO-007
- Volunteers
- 64 people
- Sponsor
- AeroRx Therapeutics Inc.
Pulmonary Disease, Chronic Obstructive
Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD
The goal of this clinical trial was to compare the action of long-acting ß2-agonists (LABA-olodaterol) and muscarinic antagonists (LAMA-tiotropium) on tissue oxygenation in COPD considering their impact on proximal and peripheral…
- Trial name
- NCT05927155
- Testing
- LABA, LAMA
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Erasme University Hospital
Pulmonary Disease, Chronic Obstructive
OTIVACTO Spain Non Interventional Study
This is a self-controlled study design enrolling consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC.
- Trial name
- NCT02927795
- Where
- 79 sites in Spain
- Volunteers
- 257 people
- Sponsor
- Boehringer Ingelheim